Drug intelligence / Profile preview

NTX-352

Development stage: Unknown
Lead developer: NeoTX Therapeutics
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

NTX-352 is a clinical-stage combination therapy program developed by NeoTX Therapeutics. It centers on naptumomab estafenatox (NAP), a tumor-targeted superantigen (TTS) biologic. NAP consists of a Fab fragment targeting the 5T4 oncofetal antigen fused to an engineered version of the staphylococcal enterotoxin A (SEA/E-120) superantigen. This superantigen component binds to the T-cell receptor (TCR) of a large subset of T cells, bypassing MHC restriction to induce a potent localized immune response within the tumor microenvironment. NTX-352 involves combining NAP with various agents, including the PD-L1 inhibitor durvalumab (in partnership with AstraZeneca), the chemotherapy docetaxel, or the personalized neoantigen peptide vaccine NeoPep GT. These combinations aim to enhance tumor-directed immune activation or leverage chemotherapy-mediated tumor killing.

Other names: NAP + durvalumabNAP + docetaxelNAP + NeoPep GT

Targets

TPBG (Trophoblast glycoprotein)TCR (T cell antigen receptor complex)

Beyond the preview

Go deeper on NTX-352.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTX-352.

Explore the full profile